Nevro Corp. (NYSE: NVRO) and SeaSpine Holdings Corporation (NASDAQ:SPNE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Nevro Corp. has a beta of -0.67, indicating that its stock price is 167% less volatile than the S&P 500. Comparatively, SeaSpine Holdings Corporation has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nevro Corp. and SeaSpine Holdings Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Nevro Corp. $277.91 million 9.25 -$22.57 million ($1.38) -63.30
SeaSpine Holdings Corporation $130.35 million 1.01 -$21.74 million ($3.18) -3.29

SeaSpine Holdings Corporation has higher revenue, but lower earnings than Nevro Corp.. Nevro Corp. is trading at a lower price-to-earnings ratio than SeaSpine Holdings Corporation, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

39.0% of SeaSpine Holdings Corporation shares are held by institutional investors. 12.1% of Nevro Corp. shares are held by company insiders. Comparatively, 14.6% of SeaSpine Holdings Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nevro Corp. and SeaSpine Holdings Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nevro Corp. 0 1 6 0 2.86
SeaSpine Holdings Corporation 0 0 3 0 3.00

Nevro Corp. presently has a consensus price target of $102.00, indicating a potential upside of 16.77%. SeaSpine Holdings Corporation has a consensus price target of $18.50, indicating a potential upside of 76.86%. Given SeaSpine Holdings Corporation’s stronger consensus rating and higher probable upside, analysts plainly believe SeaSpine Holdings Corporation is more favorable than Nevro Corp..

Profitability

This table compares Nevro Corp. and SeaSpine Holdings Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nevro Corp. -14.33% -16.25% -9.43%
SeaSpine Holdings Corporation -27.90% -32.86% -24.72%

Summary

Nevro Corp. beats SeaSpine Holdings Corporation on 7 of the 13 factors compared between the two stocks.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

SeaSpine Holdings Corporation Company Profile

SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment. It has a portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine. It offers a portfolio of orthobiologics and spinal fusion hardware products for the treatment of patients suffering from spinal and other orthopedic disorders. Its orthobiologics products consist of a range of bone graft substitutes that are designed to improve bone fusion rates following a range of orthopedic surgeries, including spine, hip and extremities procedures.

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.